ProJenX

[The ALS Association @alsassociation]

“ALS-specific biology and chemistry takes time, but careful preclinical studies are essential for more rational therapeutic candidates.”
A great thought presented by Erin Fleming, Vice President, Research and Development at ProJenX during the Built for Speed: Strategies to Improve Clinical Trial Efficiency session here at #ALSNexus!

[ProJenX @ProJenX]

Tune in next week for an update on the Phase 1 study of prosetin with Erin Fleming, our VP of R&D!

[ALS Canada @ALSCanada]

Join ALS Canada, on May 2 at 1:00 pm ET, for ALS Clinical Trials Unboxed. This month, Erin Fleming, Vice-President, Research and Development at ProJenX will present on a Phase 1 clinical study to evaluate prosetin for ALS. To register for webinar, visit https://t.co/Vvmue3BQ6h.

[NeurologyLive® @neurology_live]

Recently, the @US_FDA has lifted its partial clinical hold on @ProJenX’s hybrid phase 1 study assessing its investigational MAP4 kinase (MAP4K) inhibitor prosetin as a potential treatment for patients with #ALS. @Columbia @JinsyMd

https://t.co/nODoPwYyUy

[ProJenX @ProJenX]

@NISHwmn We couldn't agree more. Our decisions are guided by a wonderful community advisory board (more here: https://t.co/bMP7DDZisv) and we welcome additional guidance every step of the way. Please stay in touch!

[ProJenX @ProJenX]

ProJenX is excited announce the formation of our Scientific Advisory Board. This world-class group of researchers and clinicians will guide our efforts to advance prosetin in ALS and other neurodegenerative diseases. Read more here: https://t.co/rJ6DfqLo4x

[ProJenX @ProJenX]

Please contact [email protected] for more information about this study.

[ProJenX @ProJenX]

We are very excited to announce the authorization of a clinical trial application (CTA) by Health Canada for the first-in-patient study of prosetin, a novel, CNS-penetrant MAP4K inhibitor developed for ALS. Read more: https://t.co/4dZ9WKzmt7

[ProJenX @ProJenX]

From @AlexWestchester at @GENbio, a feature on the long-term research collaboration that led to our investigational drug prosetin, and our development plans in #ALS. Read more: https://t.co/1dyLgoISNf

[ProJenX @ProJenX]

We're happy to answer any questions about PRO-101 or prosetin - DMs are open, or email us anytime at [email protected].

[ProJenX @ProJenX]

We are excited to get on Twitter...and no better time to get in the #ALS conversation than the @NEALSconsortium meeting.

[ProJenX @ProJenX]

Otherwise, check out the abstract in Muscle & Nerve here: https://t.co/MKEPiYcQkE